Feed / ACHV

Achieve Life Sciences, Inc.

ACHV

Healthcare · 7.06 -3.2% today

Isolated · not yet confirmedMarket checked 11 Sept, 15:55 GMT-4

Market read

Achieve Life Sciences, Inc.'s current read is isolated; its market group is not confirming.

No new filing conclusion is available. 0 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Company-3.2% todayVolume comparison unavailable
Market group0 of 31 activePrecious Metals & Mining · unavailable
Disclosed network0 of 2 confirmingNo filing-linked name is confirming now
What would change this read
  • ACHV's market-adjusted activity becomes unusual and at least one connected name confirms.

Invalidation: The isolated read changes if ACHV's group or a disclosed connection begins moving with it.

Watch this read

Research brief

The story so far

Healthcare · Biotechnology

No new filing conclusion is available. 0 of 31 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 2 directly disclosed connections are confirming.

Evidence that supports

No thresholded supportive filing evidence is available yet.

Evidence that challenges

No thresholded adverse filing evidence is available yet.

What would clarify the read
  • ACHV's market-adjusted activity becomes unusual and at least one connected name confirms.

Company research

Understand the business, not just the ticker

As of Sep 12, 2026
Business model and earnings drivers

Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.

Key research questions
  • Which operating variable is changing?
  • Is that change durable, cyclical or one-off?
  • What evidence would disprove the current interpretation?
Annual periods2
Price observations320
Usable filing statements27
Verified relationships2
Evidence supporting the case

No qualifying supportive evidence was identified.

Evidence challenging the case

No qualifying adverse evidence was identified; that is not proof there is no downside.

Questions before a position

No credible peer-relative valuation comparison is available yet.

Longer-term price context

Price as of Sep 11, 2026

7.06
6m+52.7%12m+123.3%24m
Annual trajectory

Reported annual revenue and per-share history. This is accounting history, not a forecast.

PeriodRevenueYoYDiluted EPSShare change
2018-12-31$0
2019-12-31$0

Valuation discipline

Peer-relative valuation withheld

Jodie found no industry-matched filing peers suitable for a valuation comparison. It will not substitute broader financial-sector names.

Scenario scaffold

Fewer than 4 annual revenue periods; too little history to scaffold scenarios.

Price action

How the market is pricing the story

7.06-3.2% today

Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.

Developments

No sourced recent-development timeline yet

Jodie has not returned a relevant primary source or news item for ACHV. This is an evidence-coverage gap, not a conclusion that nothing material happened.

Business and financial condition

Reported financial figures are not available yet

Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.

Filing analysis

No comparable filing assessment is available yet

Jodie has not yet found a suitable current-versus-prior filing comparison for ACHV. This does not mean the latest filing was neutral or immaterial.

Business ecosystem

The relationships behind ACHV

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

OMCOmnicom Group Inc.partnerMay 12, 2026

Furthermore, we have entered into a partnership with Omnicom to support the commercial launch of cytisinicline in the United States, which requires financial commitments in advance of approval and may result is less oversight by us or disruption in our commer…

RSReliance, Inc.partnerNov 6, 2025

Risks Related to Our Reliance on Third Parties We expect to continue to rely on third parties to manufacture cytisinicline.

Filing peers

No filing peers are available for this name yet.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

ACHV is currently a Follower in the organic co-movement group Precious Metals & Mining. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 2 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for ACHV; it is not active in the latest market snapshot.

Context history

Theme membership history

No durable theme membership has been observed for this name yet.